However, when correlating the prognostic accuracy of the assessed genes to the established prognostic factors including patient age, ELN risk stage, and BM blasts %, it revelaed that adding CKIT, TET1, or TET2 could impove the prognosic power for prediciting relapse in AML patients. The gene discussed is TET2; the disease is acute myeloid leukemia.